A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2

BACKGROUND: Conventional cytoreductive therapy for patients with chronic Philadelphia‐negative myeloproliferative neoplasms (MPNs) includes hydroxyurea (HU), interferon‐alpha2 (IFN), and anagrelide. HU is worldwide the most used cytoreductive agent, which lowers elevated blood cell counts within day...

Descripción completa

Detalles Bibliográficos
Autores principales: Dam, Marc J. B., Pedersen, Rasmus K., Knudsen, Trine A., Andersen, Morten, Ellervik, Christina, Larsen, Morten Kranker, Kjær, Lasse, Skov, Vibe, Hasselbalch, Hans C., Ottesen, Johnny T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972145/
https://www.ncbi.nlm.nih.gov/pubmed/36254099
http://dx.doi.org/10.1002/cam4.5285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972145/
https://www.ncbi.nlm.nih.gov/pubmed/36254099
http://dx.doi.org/10.1002/cam4.5285

Ejemplares similares